FDA Clears Beam Therapeutics' BEAM-304 for PKU, Advancing Novel Base Editor to Clinic
BEAM has more than doubled off its 52-week low of $15.6.
Summary
The FDA has cleared Beam Therapeutics' Investigational New Drug (IND) application for BEAM-304, allowing the company to initiate Phase 1/2 clinical trials for the treatment of Phenylketonuria (PKU). This is a significant de-risking event, validating the preclinical data and regulatory path for a novel base-editing therapy targeting a rare metabolic disorder affecting approximately 20,000 people in the U.S. The company plans to use an innovative platform approach for multiple mutation-specific base editors within a single clinical program. This follows recent positive updates on other pipeline candidates like BEAM-302. Updated preclinical data for BEAM-304 will be presented at the FASEB Genome Engineering conference from July 6-9, 2026.
At the time of this announcement, BEAM was trading at $32.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $15.60 to $36.44. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.